Salvage Local Treatment for Localized Radio-Recurrent Prostate Cancer: A Narrative Review and Future Perspectives

References

• Schymura MJ , KahnAR, GermanRRet al. Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1). BMC Cancer.10, 152 (2010).
   PubMed Web of Science ®Google Scholar
• Zumsteg ZS , SprattDE, RomesserPBet al. Anatomical patterns of recurrence following biochemical relapse in the dose escalation era of external beam radiotherapy for prostate cancer. J. Urol.194(6), 1624–1630 (2015).
   PubMed Web of Science ®Google Scholar
• Nguyen PL , AlibhaiSMH, BasariaSet al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur. Urol.67(5), 825–836 (2015).
   PubMed Web of Science ®Google Scholar
• James ND , SydesMR, ClarkeNWet al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet387(10024), 1163–1177 (2016).
   PubMed Web of Science ®Google Scholar
• Cornford P , vanden Bergh RCN, BriersEet al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: treatment of relapsing and metastatic prostate cancer. Eur. Urol.79(2), 263–282 (2021).
   PubMed Web of Science ®Google Scholar
• Cary KC , PaciorekA, FuldeoreMJ, CarrollPR, CooperbergMR. Temporal trends and predictors of salvage cancer treatment after failure following radical prostatectomy or radiation therapy: an analysis from the CaPSURE registry. Cancer120(4), 507–512 (2014).
   PubMed Web of Science ®Google Scholar
• Zilli T , BenzE, DipasqualeG, RouzaudM, MiralbellR. Reirradiation of prostate cancer local failures after previous curative radiation therapy: long-term outcome and tolerance. Int. J. Radiat. Oncol. Biol. Phys.96(2), 318–322 (2016).
   PubMed Web of Science ®Google Scholar
• Cuccia F , MazzolaR, NicosiaLet al. Prostate re-irradiation: current concerns and future perspectives. Expert Rev Anticancer Ther.20(11), 947–956 (2020).
   PubMed Web of Science ®Google Scholar
• Mazzola R , CucciaF, FigliaVet al. New metabolic tracers for detectable PSA levels in the post-prostatectomy setting: is the era of melting glaciers upcoming? Transl Androl Urol. 8(Suppl. 5), S538–S541 (2019).
   PubMedGoogle Scholar
• Philippou Y , ParkerRA, VolanisD, GnanapragasamVJ. Comparative oncologic and toxicity outcomes of salvage radical prostatectomy versus nonsurgical therapies for radiorecurrent prostate cancer: a meta-regression analysis. Eur Urol Focus.2(2), 158–171 (2016).
   PubMedGoogle Scholar
• Ingrosso G , BecheriniC, LanciaAet al. Nonsurgical salvage local therapies for radiorecurrent prostate cancer: a systematic review and meta-analysis. Eur Urol Oncol.3(2), 183–197 (2020).
   PubMed Web of Science ®Google Scholar
• Valle LF , LehrerEJ, MarkovicDet al. A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER). Eur. Urol.8(3), 280–292 (2020).
   Google Scholar
• Cornford P , BellmuntJ, BollaMet al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur. Urol.71(4), 630–642 (2017).
   PubMed Web of Science ®Google Scholar
• Karahissarlian V , SargosP, BlaisEet al. Diagnostic performance of imaging techniques for detecting of local recurrence after prostate brachytherapy. Cancer Radiother.24(4), 323–331 (2020).
   PubMed Web of Science ®Google Scholar
• Valle LF , GreerMD, ShihJHet al. Multiparametric MRI for the detection of local recurrence of prostate cancer in the setting of biochemical recurrence after low dose rate brachytherapy. Diagn Interv Radiol.24(1), 46–53 (2018).
   PubMed Web of Science ®Google Scholar
• Kowa J-Y , SonejiN, SohaibSAet al. Detection and staging of radio-recurrent prostate cancer using multiparametric MRI. Br. J. Radiol.94(1120), 20201423 (2021).
   PubMed Web of Science ®Google Scholar
• Panebianco V , VilleirsG, WeinrebJCet al. Prostate magnetic resonance imaging for local recurrence reporting (PI-RR): international consensus-based guidelines on multiparametric magnetic resonance imaging for prostate cancer recurrence after radiation therapy and radical prostatectomy. Eur Urol Oncol.doi:10.1016/j.euo.2021.01.003 (2021) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Perera M , PapaN, RobertsMet al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur. Urol.77(4), 403–417 (2020).
   PubMed Web of Science ®Google Scholar
• Evangelista L , ZattoniF, GuttillaAet al. Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis. Clin. Nucl. Med.38(5), 305–314 (2013).
   PubMed Web of Science ®Google Scholar
• Tanaka T , YangM, FroemmingATet al. Current imaging techniques for and imaging spectrum of prostate cancer recurrence and metastasis: a pictorial review. Radiographics40(3), 709–726 (2020).
   PubMed Web of Science ®Google Scholar
• Pfister D , HaidlF, NestlerTet al. 68 Ga-PSMA-PET/CT helps to select patients for salvage radical prostatectomy with local recurrence after primary radiotherapy for prostate cancer. BJU Int.126(6), 679–683 (2020).
   PubMed Web of Science ®Google Scholar
• Jansen BHE , van LeeuwenPJ, WondergemMet al. Detection of recurrent prostate cancer using prostate-specific membrane antigen positron emission tomography in patients not meeting the Phoenix Criteria for biochemical recurrence after curative radiotherapy. Eur Urol Oncol.doi:10.1016/j.euo.2020.01.002 (2020) ( Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Crook JM , RodgersJ, PisanskyTMet al. Salvage low dose rate prostate brachytherapy: clinical outcomes of a phase II trial for local recurrence after external beam radiotherapy (NRG/RTOG-0526). Int. J. Radiat. Oncol. Biol. Phys.108(3), S3 (2020).
   PubMed Web of Science ®Google Scholar
• Marra G , KarnesRJ, CallerisGet al. Oncological outcomes of salvage radical prostatectomy for recurrent prostate cancer in the contemporary era: a multicenter retrospective study. Urol Oncol.39(5), 296.e21–296.e29 (2021).
   PubMed Web of Science ®Google Scholar
• Calleris G , MarraG, DalmassoEet al. Is it worth to perform salvage radical prostatectomy for radio-recurrent prostate cancer? A literature review. World J. Urol.37(8), 1469–1483 (2019).
   PubMed Web of Science ®Google Scholar
• Chade DC , EasthamJ, GraefenMet al. Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature. Eur. Urol.61(5), 961–971 (2012).
   PubMed Web of Science ®Google Scholar
• Gontero P , MarraG, AlessioPet al. Salvage radical prostatectomy for recurrent prostate cancer: morbidity and functional outcomes from a large multicenter series of open versus robotic approaches. J. Urol.202(4), 725–731 (2019).
   PubMed Web of Science ®Google Scholar
• Ahallal Y , ShariatSF, ChadeDCet al. Pilot study of salvage laparoscopic prostatectomy for the treatment of recurrent prostate cancer. BJU Int.108(5), 724–728 (2011).
   PubMed Web of Science ®Google Scholar
• Wetherell D , BoltonD, KavanaghL, PereraM. Current role of salvage robotic-assisted laparoscopic prostatectomy. World J. Urol.31(3), 463–469 (2013).
   PubMed Web of Science ®Google Scholar
• Marta F-P , BelénC-R, ManuelC-SJ, AntonioM-LR. Salvage robotic prostatectomy after brachytherapy. Clin. Oncol.1, 1104 (2016).
   Google Scholar
• De Groote R , NathanA, DeBleser Eet al. Techniques and outcomes of salvage robot-assisted radical prostatectomy (sRARP). Eur. Urol.78(6), 885–892 (2020).
   PubMed Web of Science ®Google Scholar
• Pokala N , HuynhDL, HendersonAA, JohansC. Survival outcomes in men undergoing radical prostatectomy after primary radiation treatment for adenocarcinoma of the prostate. Clin Genitourin. Cancer.14(3), 218–225 (2016).
   PubMed Web of Science ®Google Scholar
• Mandel P , SteuberT, AhyaiSet al. Salvage radical prostatectomy for recurrent prostate cancer: verification of European Association of Urology guideline criteria. BJU Int.117(1), 55–61 (2016).
   PubMed Web of Science ®Google Scholar
• Habl G , SauterK, SchillerKet al. 68 Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: individualized medicine or new standard in salvage treatment. Prostate.77(8), 920–927 (2017).
   PubMed Web of Science ®Google Scholar
• Yuh B , RuelN, MuldrewSet al. Complications and outcomes of salvage robot-assisted radical prostatectomy: a single-institution experience. BJU Int.113(5), 769–776 (2014).
   PubMed Web of Science ®Google Scholar
• Kaffenberger SD , KeeganKA, BansalNKet al. Salvage robotic assisted laparoscopic radical prostatectomy: a single institution, 5-year experience. J. Urol.189(2), 507–513 (2013).
   PubMed Web of Science ®Google Scholar
• Kenney PA , NawafCB, MustafaMet al. Robotic-assisted laparoscopic versus open salvage radical prostatectomy following radiotherapy. Can J Urol.23(3), 8271–8277 (2016).
   PubMed Web of Science ®Google Scholar
• Rocco B , CozziG, SpinelliMGet al. Current status of salvage robot-assisted laparoscopic prostatectomy for radiorecurrent prostate cancer. Curr Urol Rep.13(3), 195–201 (2012).
   PubMed Web of Science ®Google Scholar
• Parekh A , GrahamPL, NguyenPL. Cancer control and complications of salvage local therapy after failure of radiotherapy for prostate cancer: a systematic review. Semin Radiat Oncol.23(3), 222–234 (2013).
   PubMed Web of Science ®Google Scholar
• Kollmeier MA , McBrideS, TaggarAet al. Salvage brachytherapy for recurrent prostate cancer after definitive radiation therapy: a comparison of low-dose-rate and high-dose-rate brachytherapy and the importance of prostate-specific antigen doubling time. Brachytherapy.16(6), 1091–1098 (2017).
   PubMed Web of Science ®Google Scholar
• Moman MR , vander Poel HG, BattermannJJ, MoerlandMA, van VulpenM. Treatment outcome and toxicity after salvage 125-I implantation for prostate cancer recurrences after primary 125-I implantation and external beam radiotherapy. Brachytherapy.9(2), 119–125 (2010).
   PubMed Web of Science ®Google Scholar
• Burri RJ , StoneNN, UngerP, StockRG. Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys.77(5), 1338–1344 (2010).
   PubMed Web of Science ®Google Scholar
• Henríquez López I , González-SanSegundo C, VegasJOet al. Salvage brachytherapy for locally-recurrent prostate cancer after radiation therapy: a comparison of efficacy and toxicity outcomes with high-dose rate and low-dose rate brachytherapy. Radiother. Oncol.141, 156–163 (2019).
   PubMed Web of Science ®Google Scholar
• Crook J , MaloneS, PerryG, BahadurY, RobertsonS, AbdolellM. Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. Int. J. Radiat. Oncol. Biol. Phys.48(2), 355–367 (2000).
   PubMed Web of Science ®Google Scholar
• Yamada Y , KollmeierMA, PeiXet al. A Phase II study of salvage high-dose-rate brachytherapy for the treatment of locally recurrent prostate cancer after definitive external beam radiotherapy. Brachytherapy.13(2), 111–116 (2014).
   PubMed Web of Science ®Google Scholar
• Wojcieszek P , SzlagM, GłowackiGet al. Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer after primary radiotherapy failure. Radiother. Oncol.119(3), 405–410 (2016).
   PubMed Web of Science ®Google Scholar
• Vargas C , SwartzD, VashiAet al. Salvage brachytherapy for recurrent prostate cancer. Brachytherapy.13(1), 53–58 (2014).
   PubMed Web of Science ®Google Scholar
• Rose JN , CrookJM, PicklesT, KeyesM, MorrisWJ. Salvage low-dose-rate permanent seed brachytherapy for locally recurrent prostate cancer: association between dose and late toxicity. Brachytherapy.14(3), 342–349 (2015).
   PubMed Web of Science ®Google Scholar
• González-San Segundo C , JovéJ, ZapateroAet al. Survival after biochemical failure in prostate cancer treated with radiotherapy: Spanish Registry of Prostate Cancer (RECAP) database outcomes. Clin Transl Oncol.21(8), 1044–1051 (2019).
   PubMed Web of Science ®Google Scholar
• Crook JM , ZhangP, PisanskyTMet al. A prospective phase 2 trial of transperineal ultrasound-guided brachytherapy for locally recurrent prostate cancer after external beam radiation therapy (NRG Oncology/RTOG-0526). Int. J. Radiat. Oncol. Biol. Phys.103(2), 335–343 (2019).
   PubMed Web of Science ®Google Scholar
• Nguyen PL , ChenM-H, D'AmicoAVet al. Magnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorable-risk prostate cancer: a prospective phase 2 study. Cancer110(7), 1485–1492 (2007).
   PubMed Web of Science ®Google Scholar
• Tisseverasinghe SA , CrookJM. The role of salvage brachytherapy for local relapse after external beam radiotherapy for prostate cancer. Transl Androl Urol.7(3), 414–435 (2018).
   PubMed Web of Science ®Google Scholar
• Kaljouw E , PietersBR, KovácsG, HoskinPJ. A Delphi consensus study on salvage brachytherapy for prostate cancer relapse after radiotherapy, a Uro-GEC study. Radiother. Oncol.118(1), 122–130 (2016).
   PubMed Web of Science ®Google Scholar
• Onol FF , BhatS, MoschovasMet al. Comparison of outcomes of salvage robot-assisted laparoscopic prostatectomy for post-primary radiation vs focal therapy. BJU Int.125(1), 103–111 (2020).
   PubMed Web of Science ®Google Scholar
• van Son M , PetersM, MoerlandM, KerkmeijerL, LagendijkJ, vander Voort van Zyp J. Focal salvage treatment of radiorecurrent prostate cancer: a narrative review of current strategies and future perspectives. Cancers (Basel).10(12), 480 (2018).
   PubMed Web of Science ®Google Scholar
• de Castro Abreu AL , BahnD, LeslieSet al. Salvage focal and salvage total cryoablation for locally recurrent prostate cancer after primary radiation therapy. BJU Int.112(3), 298–307 (2013).
   PubMed Web of Science ®Google Scholar
• Safavy S , JabajiRB, LuSMet al. Salvage cryoablation for radiorecurrent prostate cancer: initial experience at a regional health care system. Perm J.23, 18–153 (2019).
   PubMedGoogle Scholar
• Devos B , AlHajj Obeid W, AndrianneCet al. Salvage high-intensity focused ultrasound versus salvage radical prostatectomy for radiation-recurrent prostate cancer: a comparative study of oncological, functional, and toxicity outcomes. World J. Urol.37(8), 1507–1515 (2019).
   PubMed Web of Science ®Google Scholar
• Siddiqui Khurram M , BilliaM, ArifinA, LiFan, VioletteP, ChinJoseph L. Pathological, oncologic and functional outcomes of a prospective registry of salvage high intensity focused ultrasound ablation for radiorecurrent prostate cancer. J. Urol.197(1), 97–102 (2017).
   PubMed Web of Science ®Google Scholar
• Murat F-J , PoissonnierL, RabilloudMet al. Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer. Eur. Urol.55(3), 640–647 (2009).
   PubMed Web of Science ®Google Scholar
• Baco E , GeletA, CrouzetSet al. Hemi salvage high-intensity focused ultrasound (HIFU) in unilateral radiorecurrent prostate cancer: a prospective two-centre study. BJU Int.114(4), 532–540 (2014).
   PubMed Web of Science ®Google Scholar
• Pasticier G , ChapetO, BadetLet al. Salvage radiotherapy after high-intensity focused ultrasound for localized prostate cancer: early clinical results. Urology72(6), 1305–1309 (2008).
   PubMed Web of Science ®Google Scholar
• Corkum MT , MendezLC, ChinJ, D'SouzaD, BoldtRG, BaumanGS. A novel salvage option for local failure in prostate cancer, reirradiation using external beam or stereotactic radiation therapy: systematic review and meta-analysis. Adv Radiat. Oncol.5(5), 965–977 (2020).
   PubMedGoogle Scholar
• Fuller D , WurzerJ, ShiraziRet al. Retreatment for local recurrence of prostatic carcinoma after prior therapeutic irradiation: efficacy and toxicity of HDR-Like SBRT. Int. J. Radiat. Oncol. Biol. Phys.106(2), 291–299 (2020).
   PubMed Web of Science ®Google Scholar
• Bergamin S , EadeT, KneeboneAet al. Interim results of a prospective prostate-specific membrane antigen-directed focal stereotactic reirradiation trial for locally recurrent prostate cancer. Int. J. Radiat. Oncol. Biol. Phys.108(5), 1172–1178 (2020).
   PubMed Web of Science ®Google Scholar
• Pasquier D , MartinageG, JanorayGet al. Salvage stereotactic body radiation therapy for local prostate cancer recurrence after radiation therapy: a retrospective multicenter study of the GETUG. Int. J. Radiat. Oncol. Biol. Phys.. 105(4), 727–734 (2019).
   PubMed Web of Science ®Google Scholar
• Ginsburg KB , ElshafeiA, YuC, JonesJS, CherML. Avoidance of androgen deprivation therapy in radiorecurrent prostate cancer as a clinically meaningful endpoint for salvage cryoablation. Prostate. 77(14), 1446–1450 (2017).
   PubMed Web of Science ®Google Scholar
• Zapatero A , GuerreroA, MaldonadoXet al. Late radiation and cardiovascular adverse effects after androgen deprivation and high-dose radiation therapy in prostate cancer: results from the DART 01/05 Randomized Phase 3 Trial. Int. J. Radiat. Oncol. Biol. Phys.96(2), 341–348 (2016).
   PubMed Web of Science ®Google Scholar
• Shipley WU , SeiferheldW, LukkaHRet al. Radiation with or without antiandrogen therapy in recurrent prostate cancer. N. Engl. J. Med.376(5), 417–428 (2017).
   PubMed Web of Science ®Google Scholar
• Carrie C , MagnéN, Burban-ProvostPet al. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncol.20(12), 1740–1749 (2019).
   PubMed Web of Science ®Google Scholar
• Couñago F , López-CamposF, Díaz-GavelaAAet al. Clinical applications of molecular biomarkers in prostate cancer. Cancers (Basel).12(6), (2020).
   Web of Science ®Google Scholar
• Spratt DE , YousefiK, DeheshiSet al. Individual patient-level meta-analysis of the performance of the decipher genomic classifier in high-risk men after prostatectomy to predict development of metastatic disease. J. Clin. Oncol.35(18), 1991–1998 (2017).
   PubMed Web of Science ®Google Scholar
• Dalela D , Santiago-JiménezM, YousefiKet al. Genomic classifier augments the role of pathological features in identifying optimal candidates for adjuvant radiation therapy in patients with prostate cancer: development and internal validation of a multivariable prognostic model. J. Clin. Oncol.35(18), 1982–1990 (2017).
   PubMed Web of Science ®Google Scholar
• Gore JL , du PlessisM, Santiago-JiménezMet al. Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: interim results from the Multicenter Prospective PRO-IMPACT study. Cancer123(15), 2850–2859 (2017).
   PubMed Web of Science ®Google Scholar